Back to Search
RON WEXLER, M.D.
M.D.
Cardiovascular Disease Physician
NPI: 1992067938IndividualAccepts Medicare
Specialties, Licenses & Credentials
Cardiovascular Disease PhysicianPrimary
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
70410(MN)
CMS Specialties
PrimaryCARDIOVASCULAR DISEASE (CARDIOLOGY)
Education
UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY
Class of 2012
Research & Publications (20)
Sociology meets genetics: sociogenetic implications for future management of hypertension and heart failure.
PMID 19627663·Curr Treat Options Cardiovasc Med·2009
8-other
Physician reported perception in the treatment of high blood pressure does not correspond to practice.
PMID 19341474·BMC Fam Pract·2009
8-other
Prevention of heat-related illness: a new modality offers new insight.
PMID 19434027·South Med J·2009
8-other
Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.
PMID 19046881·Bioorg Med Chem Lett·2009
7-preclinical
Combination of ARB and ACE inhibitors in heart failure patients.
PMID 19323357·Am Fam Physician·2009
8-other
Barriers to blood pressure control as reported by African American patients.
PMID 19585931·J Natl Med Assoc·2009
8-other
Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties.
PMID 18424044·Bioorg Med Chem Lett·2008
7-preclinical
Sulfonamidolactam inhibitors of coagulation factor Xa.
PMID 18329876·Bioorg Med Chem Lett·2008
8-other
Medication nonadherence for blood pressure control is primarily a physician-related factor.
PMID 18809823·Arch Intern Med·2008
8-other
Letter by Wexler and Feldman regarding article, "Socioeconomic position, race/ethnicity, and inflammation in the multi-ethnic study of atherosclerosis".
PMID 18490530·Circulation·2008
8-other
Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of Factor Xa.
PMID 18550370·Bioorg Med Chem Lett·2008
8-other
Onward, Christian penguins: wildlife film and the image of scientific authority.
PMID 18761279·Stud Hist Philos Biol Biomed Sci·2008
7-preclinical
Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.
PMID 18315548·J Thromb Haemost·2008
7-preclinical
Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.
PMID 18054227·Bioorg Med Chem Lett·2008
7-preclinical
N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerations.
PMID 17914718·J Pharm Sci·2008
7-preclinical
Management strategies for stage-D patients with acute heart failure.
PMID 17957741·Clin Cardiol·2008
6-review
Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
PMID 17914785·J Med Chem·2007
7-preclinical
Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors.
PMID 17933529·Bioorg Med Chem Lett·2007
4-observational
Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors.
PMID 17994684·J Med Chem·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 640 JACKSON ST
SAINT PAUL, MN 55101 - Phone
- (651) 254-4887
Quick Facts
- NPI
- 1992067938
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 14
- Publications
- 20
Are you this provider?
Claim Your Profile